________________________________________________________________________________________________
CordenPharma include custom lipid manufacturing , standard lipids , LNP starter kits , and lipid excipient technologies like SORT-Coated LNPs and lipopeptides to support , for example , ADME and DMPK activities .
Committed to quality
To learn more about CordenPharma ’ s evolution and capabilities , we sit down with Matthieu Giraud , Senior Platform Director , Global Lipids & Carbohydrates . “ We have an excellent track record here at CordenPharma and we collaborate extensively with the research , pharmaceutical , and diagnostic sectors to deliver cutting-edge solutions that push the boundaries of science and contribute to saving lives ,” Matthieu begins . “ Our unwavering commitment to quality across all our products and services forms the bedrock of our reputation as a leading CDMO with specialized experience across multiple platforms .
“ We are driven by a deep passion for unlocking the potential of lipid-based therapeutics , and as such have built a team of lipid experts and technologies to produce highly pure lipids to support the extraordinary benefits they bring to our customers . This fuels our continuous pursuit of innovation , expanding our diverse portfolio with products that positively impact our customers and the lives of their patients . Our adaptability and responsiveness to dynamic market needs empower us to creatively transform challenges into solutions , supporting innovators in the development of groundbreaking medicines .”
Also , with decades of experience in developing and manufacturing APIs , CordenPharma works with customers to deliver critical high-quality drug substances that seamlessly support their supply chain . Within the field of APIs , the company ’ s capabilities include peptides , oligonucleotides , HPAPIs , small molecules , and API support services like Supercritical Fluid Chromatography ( SFC ), flow chemistry , solid state , and purification .
Ideal partnership
In January 2024 , CordenPharma announced a strategic alliance with pHLIP to develop the pHLIP LNP targeted delivery platform for RNA and gene therapies . Matthieu elaborates : “ Inspired by the message provided by Katalin Karikó and Drew Weissman , who were awarded the Nobel Prize in medicine for modifying mRNA to be accepted into the body , that ‘ the future of gene therapy is based on target delivery ,’ we explored strategic opportunities to bring this revolutionary approach to our customers , and in that pursuit , we found pHLIP to be the ideal partner .
“ This alliance combines our LNP technology and good manufacturing processes ( GMP ) expertise with pHLIP ’ s drug development and proprietary pH ( Low )
manufacturing-today . com 91